Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbio Co's revenue for the
three
months ended in Jun. 2026 was NT$479 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1,965 Mil.
Microbio Co's Revenue per Share for the
three
months ended in Jun. 2026 was NT$0.82.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$3.34.
During the past 12 months, the average Revenue per Share Growth Rate of Microbio Co was 8.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Microbio Co's highest 3-Year average Revenue per Share Growth Rate was 34.30% per year. The lowest was -2.50% per year. And the median was 3.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Microbio Co Revenue Related Terms
Microbio Co Revenue Historical Data
* Premium members only.
The historical data trend for Microbio Co's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Microbio Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbio Co Revenue vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Microbio Co's Revenue distribution charts can be found below:
* The bar in red indicates where Microbio Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,965 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbio Co (ROCO:4128) has a Revenue of NT$1,965 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Microbio Co and its competitors.
Is Microbio Co's Revenue too high?
Microbio Co's current Revenue is NT$1,965 Mil. Overall, Microbio Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Microbio Co's Revenue compare to KHC and GIS?
Microbio Co's Revenue of NT$1,965 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Consumer Packaged Goods company?
A good Revenue depends on the Consumer Packaged Goods industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Microbio Co and its competitors. Microbio Co's current Revenue is NT$1,965 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbio Co stock overvalued right now?
Based on GuruFocus' analysis, Microbio Co (ROCO:4128) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$36.98, compared to a current price of NT$15.60 — trading 57.8% below its estimated fair value. The current Revenue is NT$1,965 Mil. Microbio Co's overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Microbio Co (ROCO:4128), the current Revenue is NT$1,965 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbio Co (ROCO:4128) Overvalued in 2026?
Based on GuruFocus' analysis, Microbio Co stock appears to be undervalued.
The current stock price of NT$15.60 is trading 57.8% below its estimated GF Value™ of NT$36.98.
GuruFocus considers Microbio Co to be Significantly Undervalued.
Key valuation signals for ROCO:4128:
Revenue: NT$1,965 Mil
GF Value™: NT$36.98 vs. price of NT$15.60 (57.8% below fair value)
No single metric tells the full story. See the ROCO:4128 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbio Co Ltd is engaged in the research and development, manufacturing, and trading of biotech drugs and dietary supplements. Its drug portfolio includes MS-20, a mixture of soybean fermentation metabolites, which improves fatigue and loss of appetite in cancer patients undergoing chemotherapy. In addition, the company also offers Lee Herb series of herbal essence drinks, Tien Chun Bao oral solutions, Herbiron oral solutions for iron deficiency, and other pharmaceutical and organic products. The company generates revenue from biotech drug research and development and the sale of dietary supplements. The majority of its revenue is generated from the sale of its dietary supplements.
56GF Score
Get the complete analysis for ROCO:4128
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4128 has been successfully added to your 
